Jun Takizawa

Niigata, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 78 publications

Allogeneic hematopoietic stem cell transplantation achieves complete response in refractory primary mediastinal large B-cell lymphoma after the failure of chemotherapy, CAR-T therapy, and PD-1 blockade.

Allogeneic hematopoietic stem cell transplantation achieves complete response in refractory primary mediastinal large B-cell lymphoma after the failure of chemotherapy, CAR-T therapy, and PD-1 blockade.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: July 30, 2026

Response to comments on "Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan".

Response to comments on "Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan".

Journal: International journal of hematology

Published: June 18, 2026

Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.

Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.

Journal: Annals of hematology

Published: January 13, 2026

Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan.

Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan.

Journal: International journal of hematology

Published: October 21, 2025

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study.

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study.

Journal: International journal of hematology

Published: August 20, 2025

A phase 2 study of ibrutinib with venetoclax in Japanese patients with untreated CLL and SLL.

A phase 2 study of ibrutinib with venetoclax in Japanese patients with untreated CLL and SLL.

Journal: International journal of hematology

Published: August 20, 2025

Treatment initiation by positive liquid biopsy alone in primary central nervous system lymphoma: A retrospective analysis of a multi-institutional study.

Treatment initiation by positive liquid biopsy alone in primary central nervous system lymphoma: A retrospective analysis of a multi-institutional study.

Journal: Neuro-oncology advances

Published: July 20, 2025

Fatal SARS-CoV-2 Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia.

Fatal SARS-CoV-2 Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia.

Journal: Cureus

Published: July 01, 2025

Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study.

Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study.

Journal: Leukemia

Published: October 04, 2024

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial.

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial.

Journal: EClinicalMedicine

Published: September 03, 2024

Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study.

Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study.

Journal: Hematological oncology

Published: August 27, 2024

Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study.

Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study.

Journal: International journal of hematology

Published: August 21, 2024

Showing 1-12 of 78

Last Updated: 09/26/2026